PHAT logo

Phathom Pharmaceuticals, Inc. (PHAT) EBITDA

annual EBITDA:

-$261.52M-$102.47M(-64.43%)
December 31, 2024

Summary

  • As of today (September 16, 2025), PHAT annual EBITDA is -$261.52 million, with the most recent change of -$102.47 million (-64.43%) on December 31, 2024.
  • During the last 3 years, PHAT annual EBITDA has fallen by -$124.95 million (-91.49%).
  • PHAT annual EBITDA is now -20411.53% below its all-time high of -$1.27 million, reached on December 31, 2018.

Performance

PHAT EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPHATincome statement metrics

quarterly EBITDA:

-$58.12M+$17.95M(+23.59%)
June 30, 2025

Summary

  • As of today (September 16, 2025), PHAT quarterly EBITDA is -$58.12 million, with the most recent change of +$17.95 million (+23.59%) on June 30, 2025.
  • Over the past year, PHAT quarterly EBITDA has increased by +$15.37 million (+20.91%).
  • PHAT quarterly EBITDA is now -20221.68% below its all-time high of -$286.00 thousand, reached on September 30, 2018.

Performance

PHAT quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPHATincome statement metrics

TTM EBITDA:

-$256.75M+$15.37M(+5.65%)
June 30, 2025

Summary

  • As of today (September 16, 2025), PHAT TTM EBITDA is -$256.75 million, with the most recent change of +$15.37 million (+5.65%) on June 30, 2025.
  • Over the past year, PHAT TTM EBITDA has dropped by -$18.43 million (-7.73%).
  • PHAT TTM EBITDA is now -89674.48% below its all-time high of -$286.00 thousand, reached on September 30, 2018.

Performance

PHAT TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPHATincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

PHAT EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-64.4%+20.9%-7.7%
3 y3 years-91.5%-28.9%-70.2%
5 y5 years-4.2%-194.1%-27.0%

PHAT EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-91.5%at low-104.3%+23.6%-86.1%+5.7%
5 y5-year-110.6%at low-194.1%+23.6%-106.8%+5.7%
alltimeall time<-9999.0%at low<-9999.0%+40.1%<-9999.0%+5.7%

PHAT EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$58.12M(-23.6%)
-$256.75M(-5.6%)
Mar 2025
-
-$76.07M(+36.7%)
-$272.12M(+4.1%)
Dec 2024
-$261.52M(+64.4%)
-$55.66M(-16.8%)
-$261.52M(-3.9%)
Sep 2024
-
-$66.90M(-9.0%)
-$272.21M(+14.2%)
Jun 2024
-
-$73.48M(+12.2%)
-$238.33M(+21.6%)
Mar 2024
-
-$65.47M(-1.3%)
-$196.07M(+23.3%)
Dec 2023
-$159.05M(-6.3%)
-$66.36M(+101.0%)
-$159.05M(+15.3%)
Sep 2023
-
-$33.02M(+5.7%)
-$137.97M(-5.9%)
Jun 2023
-
-$31.23M(+9.8%)
-$146.59M(-8.6%)
Mar 2023
-
-$28.45M(-37.2%)
-$160.47M(-5.5%)
Dec 2022
-$169.80M
-$45.28M(+8.7%)
-$169.80M(+7.9%)
Sep 2022
-
-$41.64M(-7.7%)
-$157.44M(+4.4%)
Jun 2022
-
-$45.10M(+19.4%)
-$150.84M(+7.1%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$37.78M(+14.8%)
-$140.91M(+3.2%)
Dec 2021
-$136.57M(+10.0%)
-$32.92M(-6.1%)
-$136.57M(-12.4%)
Sep 2021
-
-$35.05M(-0.3%)
-$155.98M(+1.5%)
Jun 2021
-
-$35.16M(+5.1%)
-$153.66M(+11.1%)
Mar 2021
-
-$33.45M(-36.1%)
-$138.26M(+11.4%)
Dec 2020
-$124.16M(-50.5%)
-$52.32M(+59.8%)
-$124.16M(-26.4%)
Sep 2020
-
-$32.73M(+65.6%)
-$168.81M(-16.5%)
Jun 2020
-
-$19.76M(+2.1%)
-$202.19M(-24.9%)
Mar 2020
-
-$19.35M(-80.0%)
-$269.06M(+7.7%)
Dec 2019
-$250.95M(>+9900.0%)
-$96.96M(+46.6%)
-$249.71M(+63.0%)
Sep 2019
-
-$66.12M(-23.7%)
-$153.22M(+75.3%)
Jun 2019
-
-$86.63M(>+9900.0%)
-$87.39M(>+9900.0%)
Dec 2018
-$1.27M
-$479.00K(+67.5%)
-$765.00K(+167.5%)
Sep 2018
-
-$286.00K
-$286.00K

FAQ

  • What is Phathom Pharmaceuticals, Inc. annual EBITDA?
  • What is the all time high annual EBITDA for Phathom Pharmaceuticals, Inc.?
  • What is Phathom Pharmaceuticals, Inc. annual EBITDA year-on-year change?
  • What is Phathom Pharmaceuticals, Inc. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Phathom Pharmaceuticals, Inc.?
  • What is Phathom Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
  • What is Phathom Pharmaceuticals, Inc. TTM EBITDA?
  • What is the all time high TTM EBITDA for Phathom Pharmaceuticals, Inc.?
  • What is Phathom Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

What is Phathom Pharmaceuticals, Inc. annual EBITDA?

The current annual EBITDA of PHAT is -$261.52M

What is the all time high annual EBITDA for Phathom Pharmaceuticals, Inc.?

Phathom Pharmaceuticals, Inc. all-time high annual EBITDA is -$1.27M

What is Phathom Pharmaceuticals, Inc. annual EBITDA year-on-year change?

Over the past year, PHAT annual EBITDA has changed by -$102.47M (-64.43%)

What is Phathom Pharmaceuticals, Inc. quarterly EBITDA?

The current quarterly EBITDA of PHAT is -$58.12M

What is the all time high quarterly EBITDA for Phathom Pharmaceuticals, Inc.?

Phathom Pharmaceuticals, Inc. all-time high quarterly EBITDA is -$286.00K

What is Phathom Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?

Over the past year, PHAT quarterly EBITDA has changed by +$15.37M (+20.91%)

What is Phathom Pharmaceuticals, Inc. TTM EBITDA?

The current TTM EBITDA of PHAT is -$256.75M

What is the all time high TTM EBITDA for Phathom Pharmaceuticals, Inc.?

Phathom Pharmaceuticals, Inc. all-time high TTM EBITDA is -$286.00K

What is Phathom Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

Over the past year, PHAT TTM EBITDA has changed by -$18.43M (-7.73%)
On this page